{"schema_version":"secwatch.filing_event.v1","accession":"0001831283-23-000129","form_type":"8-K","ticker":"LIANY","cik":"0001831283","company_name":"LianBio","filed_at":"2023-12-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.842334+00:00","generated_at":"2026-06-07T19:32:03.267686+00:00","sec_items":["8.01","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"LianBio confirms unsolicited $4.30/share buyout proposal from Concentra plus CVR","bullets":["Proposal: $4.30 per share cash plus a contingent value right for 80% of net proceeds from licensing or disposition of LianBio's programs.","Concentra Biosciences (controlled by Tang Capital Partners) made the offer; Tang Capital currently holds ~8.6% of LianBio.","Proposal requires LianBio to have at least $515 million in cash and cash equivalents at closing, net of liabilities and costs.","Board is reviewing the unsolicited non-binding proposal in the best interests of shareholders; further announcement expected."],"urls":{"canonical":"https://secwatch.observer/filing/0001831283-23-000129","json":"https://secwatch.observer/filing/0001831283-23-000129.json","markdown":"https://secwatch.observer/filing/0001831283-23-000129.md","text":"https://secwatch.observer/filing/0001831283-23-000129.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1831283/000183128323000129/0001831283-23-000129-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1831283/000183128323000129/lian-20231130.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T19:32:03.267686+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}